Boehringer Ingelheim collaborates with the Broad Institute
Boehringer Ingelheim and researchers at the Broad Institute of MIT and Harvard are collaborating to tackle the unmet needs of people living with mental health conditions.
Search
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Innovation from within
Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.
Do you take periodontal disease in dogs seriously? We do!
Periodontal Disease? Brushing teeth is vital to prevent doggy breath, but not enough to ensure animal health and well-being
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Mental health: a $1 trillion burden demanding policy action
Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
Your dog’s life stages: dog health from puppy to adult and senior
The needs of dogs change as they age. Find out how to take care of their health at all stages of life: from puppy to adult and senior.
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Transboundary animal diseases (TADs)
Avian influenza? Bluetongue virus? FMD? Learn what are transboundary animal diseases and how they can impact us
Social health and wellbeing
Social health and wellbeing
Health equity for underserved communities
Introducing initiatives that improve access to healthcare for underserved communities
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
A lifetime for patients with mental health conditions
Chris Underhill is a social entrepreneur and participant at the Making More Health Convention.
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
How mobile medical clinics tackle health equity Down Under
We support Heart of Australia to improve health in rural communities
Innovation & Opportunity for Tech in Pharma
Boehringer Ingelheim’s Meet & Greet at the Women in Tech Global Conference
Reduction of Salmonella in swine after vaccination
Authorities acknowledge reduction of Salmonella after vaccination with Enterisol® Ileitis
Are you missing the bigger picture on mental health?
Revolutionizing our approach to serious mental health conditions is crucial for tailored care, placing those with lived experience at the center.
TwistPak Mixing platform for swine vaccines
TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
A career at the intersection of science and marketing
A member of the Animal Health digital marketing team, our colleague Missy talks about her purpose to bring transformative technologies to the vet community
Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Financial health
We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones